Research

Prevention of HCC Related to Metabolic Syndrome

Master
Heading

About the Program

Content

Prevention of HCC Related to Metabolic Syndrome was awarded to our researchers by the National Cancer Institute in 2022 with the goal of reducing the burden of liver cancer in patients with metabolic dysfunction.

Hepatocelluar carcinoma (HCC) is the fastest growing cause of cancer deaths among Americans. In the past decade, there has been an epidemic increase in metabolic (dysfunction) associated fatty liver disease (MAFLD)-related cirrhosis and HCC. MAFLD is estimated to affect 1 billion individuals globally and is projected to become the leading cause of HCC in the next 2 decades.

There is an urgent need to develop effective strategies to reduce HCC burden in the growing MAFLD population. The overall goal of this project is to reduce the burden of HCC-related mortality through better understanding of contemporary risk factors (e.g., metabolic traits and biomarkers) and protective factors (e.g., chemoprevention, HCC surveillance) of HCC related to MAFLD. We propose three highly integrated studies. Central to this project is leveraging and expanding our multicity, prospective cohort of persons with MAFLD-related cirrhosis, the Texas HCCC Consortium (THCCC) Cohort, which will serve as a resource for the proposed studies.

Heading

Baylor receives NCI grant to study liver cancer risk and prevention

Media Component
Dan L Duncan Comprehensive Cancer Center Front Desk
Content

Aug. 4, 2022: Researchers at Baylor College of Medicine received a five-year, $5.5 million-plus grant from the National Cancer Institute for research on liver cancer risk factors and prevention, with the goal of reducing the burden of liver cancer in patients with metabolic dysfunction.

View Article
Back to topback-to-top